ArticleNeuro-oncology2022
Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review.Frontiers in oncology · 2025Pooled it
- Utility and limitations of 18F-fluciclovine PET for biopsy targeting in a nonenhancing diffuse glioma with a gliomatosis cerebri-like growth pattern: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging in Neuro-oncology.Seminars in neurology · 2025Review
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- Multiomic profiling of glioblastoma metabolic lesions reveals complex intratumoral genomic evolution and dipeptidase-1-driven vascular proliferation.Neuro-oncology · 2025Article
- Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.Biomolecules · 2025Review
- Theranostics and molecular imaging in neuro-oncology: The beginning of a new era.Neuro-oncology · 2024Article
- PET imaging of gliomas: Status quo and quo vadis?Neuro-oncology · 2024Review
- Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.Neuro-oncology · 2024Review
- Introducing the American Society of Neuroradiology PET-Guided Diagnosis and Management in Neuro-Oncology Study Group.AJNR. American journal of neuroradiology · 2024Article
- Glioma.Nature reviews. Disease primers · 2024Review
- Introduction to the Special Issue on "Role of Novel Imaging Technique in Brain Tumors".Cancers · 2024Article
- The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic Glioblastoma.Biomedicines · 2024Article
- [Frontiers in oncology · 2024Article
- Postoperative [European journal of nuclear medicine and molecular imaging · 2023Article
- A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.The Lancet. Oncology · 2023Review
- Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution.Science advances · 2023Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies in patients with brain tumors evaluating innovative PET tracers have been published in recent years, and the initial results are promising. Here, the Response Assessment in Neuro-Oncology (RANO) PET working group provides an overview of the literature on novel investigational PET tracers for brain tumor patients. Furthermore, newer indications of more established PET tracers for the evaluation of glucose metabolism, amino acid transport, hypoxia, cell proliferation, and others are also discussed. Based on the preliminary findings, these novel investigational PET tracers should be further evaluated considering their promising potential. In particular, novel PET probes for imaging of translocator protein and somatostatin receptor overexpression as well as for immune system reactions appear to be of additional clinical value for tumor delineation and therapy monitoring. Progress in developing these radiotracers may contribute to improving brain tumor diagnostics and advancing clinical translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.